Primaquine

Generic Name: Primaquine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁N_₃O

CAS Number: 90-34-6

Unique Ingredient Identifier: MVR3634GX1

Background: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI dis...

Indication: For the treatment of malaria.

Associated Conditions: Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia

Associated Therapies: -

Clinical Trials

A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Artemether-lumefantrine combination
Drug: chloroquine
Drug: Primaquine

First Posted Date: 2015-03-17

Last Posted Date: 2024-03-13

Lead Sponsor: Menzies School of Health Research

Target Recruit Count: 181

Registration Number: NCT02389374

Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection

Phase 4

Conditions: Plasmodium Vivax

Interventions: Drug: Primaquine

First Posted Date: 2015-02-18

Last Posted Date: 2015-10-14

Lead Sponsor: Papua New Guinea Institute of Medical Research

Target Recruit Count: 150

Registration Number: NCT02364583

Locations: 🇵🇬
PNG Institute of Medical Research, Madang, Madang Province, Papua New Guinea

Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission

Phase 3

Completed

Conditions: Malaria
Asymptomatic Malaria
Plasmodium Falciparum

Interventions: Drug: Dihydroartemisinin-piperaquine combination (Artekin)
Drug: Primaquine

First Posted Date: 2014-10-08

Last Posted Date: 2016-01-14

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 120

Registration Number: NCT02259426

Locations: 🇰🇪
ICIPE, Mbita, Nyanza, Kenya

Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria

Phase 3

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Tafenoquine Placebo
Drug: Tafenoquine
Drug: Chloroquine
Drug: Primaquine Placebo
Drug: Primaquine

First Posted Date: 2014-08-13

Last Posted Date: 2018-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 251

Registration Number: NCT02216123

Locations: 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam

Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Phase 4

Completed

Conditions: Plasmodium Vivax Infection
Plasmodium Vivax Clinical Episode
Plasmodium Falciparum Infection
Plasmodium Falciparum Clinical Episode

Interventions: Drug: Placebo
Drug: Primaquine
Drug: Chloroquine
Drug: Artemether Lumefantrine

First Posted Date: 2014-05-21

Last Posted Date: 2014-05-21

Lead Sponsor: Papua New Guinea Institute of Medical Research

Target Recruit Count: 524

Registration Number: NCT02143934

Locations: 🇵🇬
PNG Institute of Medical Research, Maprik, East Sepik Province, Papua New Guinea

Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil

Not Applicable

Completed

Conditions: Malaria

Interventions: Drug: Chloroquine
Drug: Primaquine

First Posted Date: 2014-01-23

Last Posted Date: 2018-02-07

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 119

Registration Number: NCT02043652

Locations: 🇧🇷
Hospital do Jurua, Cruzeiro do Sul, Brazil

Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: dihydroartemisinin-piperaquine
Drug: primaquine

First Posted Date: 2013-06-14

Last Posted Date: 2014-01-24

Lead Sponsor: Indonesia University

Target Recruit Count: 1488

Registration Number: NCT01878357

Locations: 🇮🇩
Kecamatan Wewiku, Betun, East Nusa Tenggara, Indonesia

Safety and Efficacy of Primaquine for P. Vivax

Not Applicable

Conditions: Malaria

Interventions: Drug: Primaquine
Drug: delayed primaquine

First Posted Date: 2013-04-23

Last Posted Date: 2013-11-08

Lead Sponsor: Menzies School of Health Research

Target Recruit Count: 180

Registration Number: NCT01837992

Locations: 🇻🇺
Northern Provincial Hospital, Nambauk Aid Post, V.F.H.A Dispensary and Fanafo Dispensary, Luganville, Sanma Province, Vanuatu
🇻🇺
Toroa Dispensary, NTM Health Centre and Vila Central Hospital, Port Vila, Shefa Province, Vanuatu
🇸🇧
Tetere Hospital, Guadalcanal Province, Honiara, Guadalcanal Province, Solomon Islands

and more 1 locations

IMPROV (Improving the Radical Cure of Vivax Malaria)

Not Applicable

Completed

Conditions: Uncomplicated Vivax Malaria

Interventions: Drug: Placebo
Drug: Primaquine

First Posted Date: 2013-03-20

Last Posted Date: 2019-09-17

Lead Sponsor: University of Oxford

Target Recruit Count: 2388

Registration Number: NCT01814683

Locations: 🇪🇹
Arba Minch Hospital, Ārba Minch, Snnpr, Ethiopia
🇦🇫
Provincial Malaria & Leishmania control program (PMLCP) Nangarhar, Jalalabad, Nangarhar, Afghanistan
🇮🇩
Tanjong Leidong District Health Center, Medan, North Sumatra, Indonesia

and more 5 locations

Primaquine Pharmacokinetics in Lactating Women and Their Infants

Phase 1

Completed

Conditions: Vivax Malaria

Interventions: Drug: Primaquine

First Posted Date: 2013-01-31

Last Posted Date: 2016-02-15

Lead Sponsor: University of Oxford

Target Recruit Count: 20

Registration Number: NCT01780753

Locations: 🇹🇭
Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy